BioCentury
ARTICLE | Financial News

BeiGene prices Hong Kong listing

August 3, 2018 4:40 PM UTC

BeiGene Ltd. (NASDAQ:BGNE) raised on Aug. 2 HK$7.1 billion (US$902.7 million) through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. BeiGene, which priced the offering toward the higher end of its proposed range of HK$94.40-HK$111.60, expects to start trading on Aug. 8.

At the HK$103 midpoint, BeiGene would have raised HK$6.8 billion ($861 million). BeiGene has allotted 5.9 million shares for local Hong Kong investors, with the remainder earmarked for global investors. Underwriters include Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank, UBS and China Renaissance...

BCIQ Company Profiles

BeiGene Ltd.

Zai Lab Ltd.